drugset / Trial / NCT05298046
Study of TAVO101 in Healthy Volunteers
RandomizedParallel-groupDouble-blindPrevention
Summary
This is a Phase 1, single ascending dose study designed to investigate TAVO101, administered as an IV infusion in healthy subjects. This study is designed to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of TAVO101.
Timeline
- Start
- 2022-05-11
- Primary completion
- 2024-06-01
- Completion
- 2024-09-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | TAVO101 | Unknown | — | Intravenous |
Indications
No indication recorded.